Federal regulators have confirmed that Artri King, a widely sold over-the-counter joint-pain supplement, contains undisclosed pharmaceutical drugs, including the steroid dexamethasone and the anti-inflammatory diclofenac. The finding links a routine arthritis remedy to hidden hormone disruption and serious endocrine disease documented in multiple peer-reviewed case reports. Patients most affected are often those already living with chronic pain and limited access to specialty care.
Why a hidden-steroid joint supplement matters now
The U.S. Food and Drug Administration (FDA) reported that the primary joint-pain supplement Artri King, marketed as an over-the-counter product, contains hidden ingredients such as dexamethasone and diclofenac, according to a public notification. Dexamethasone is a glucocorticoid that can suppress the hypothalamic-pituitary-adrenal (HPA) axis, which controls the body’s hormone response to stress. When people take it unknowingly for long periods, they can develop iatrogenic Cushing syndrome and adrenal insufficiency once the drug is stopped.
The FDA has also warned that multiple Artri and Ortiga products promoted for arthritis and joint pain may contain hidden drug ingredients, according to a broader alert on Artri and Ortiga products. This moves the issue beyond a single brand and into a category of supplements that are marketed to people with chronic musculoskeletal pain, many of whom rely on low-cost remedies when formal medical care is hard to reach.
Clinical researchers have begun to map the fallout from that hidden exposure. A report in Endocrine Practice described hypothalamic-pituitary-adrenal axis disruption in a series of three patients who had been taking Artri King, linking their hormone abnormalities to unreported glucocorticoid intake documented in the supplement, according to the peer-reviewed article on Artri King-induced HPA axis disruption. The authors showed that what looked like unexplained fatigue, infections, or blood pressure changes actually traced back to a steroid hidden inside an over-the-counter bottle.
That pattern aligns with the stage-1 hypothesis that adulterated joint supplements are disproportionately affecting patients already managing chronic pain in under-resourced systems. A hospital-based report from a safety-net facility found endocrinologic abnormalities in total joint arthroplasty patients who had used Artri King and related over-the-counter supplements, according to a clinical analysis of endocrinologic abnormalities. In that setting, patients often arrived only when complications were severe enough to require surgery or hospitalization, which is when the hidden hormone disruption finally became visible.
The evidence behind the hormone disruption warnings
The FDA’s chemistry findings are the backbone of the regulatory case. In its public notification on Artri King, the agency stated that laboratory testing detected undeclared dexamethasone and diclofenac in products marketed as dietary supplements, according to the Artri King notification. Because these are active pharmaceutical ingredients, the agency treats the products as unapproved drugs that expose consumers to prescription-strength medications without medical supervision.
The pattern is not limited to one label. FDA scientists also analyzed another over-the-counter joint supplement, ADVANCE KING, and confirmed undeclared dexamethasone, diclofenac, and methocarbamol, according to an alert that ADVANCE KING may be harmful due to hidden drug ingredients. The presence of dexamethasone again links this product to potential HPA-axis suppression, while diclofenac and methocarbamol add risks of gastrointestinal, renal, and central nervous system side effects.
The enforcement trail shows how regulators are trying to cut off supply. The FDA issued warning letters to major retailers and distributors involved with Artri and Ortiga products, according to its notice cautioning consumers not to purchase or use Artri and Ortiga products. Separate warning letters were directed at Naturista Store LLC for ADVANCE KING and at Latin Foods Market for Artri-branded items, according to the agency’s compliance records on Naturista Store LLC and on Latin Foods Market. Those letters describe the products as misbranded and unapproved, and they lay out the expectation that distributors stop selling them.
Regulators have also used recalls to remove specific lots from the market. Latin Foods Market initiated a voluntary nationwide recall of Artri King Reforzado Con Ortiga Y Omega 3 after tests showed undeclared diclofenac and dexamethasone, according to the FDA’s recall notice on Artri King Reforzado. The recall highlights that these adulterated products had already entered normal retail channels before regulators intervened.
International agencies have reached similar conclusions. Australia’s Therapeutic Goods Administration (TGA) issued a safety alert after Artri King tablets were found to contain undisclosed dexamethasone and diclofenac, according to the TGA’s notice on Artri King tablets. That alert confirms that the problem is not confined to one country’s supply chain and that cross-border distribution of these products can spread risk across health systems.
Clinical evidence connects those chemical findings to real patients. A peer-reviewed case report in Case Reports in Endocrinology described a person who developed iatrogenic Cushing syndrome and subsequent adrenal insufficiency after taking Artri Ajo King, attributing the condition to a hidden glucocorticoid ingredient identified in regulatory testing, according to the article on Cushing syndrome from Artri Ajo King. Another peer-reviewed case in Cureus documented iatrogenic Cushing’s syndrome with HPA-axis suppression linked to Artri King exposure, referencing FDA public notifications as part of the evidence trail, according to the report on Cushing’s syndrome and Artri King.
Beyond individual cases, a peer-reviewed analysis in The American Journal of Medicine described severe adrenal insufficiency in hospitalized patients who had taken glucocorticoid-containing supplements similar to Artri King and Ortiga products, according to the abstract on surreptitious glucocorticoid-containing supplements. The authors explained that because the steroids are hidden, clinicians often do not suspect supplement-related adrenal suppression until patients present with shock, infection, or other acute crises.
The safety-net hospital report adds a population glimpse. Researchers observed endocrinologic abnormalities among total joint arthroplasty patients who reported using Artri King and related over-the-counter supplements, according to the study on Artri King and OTC supplements. The authors argued that unprescribed systemic corticosteroid exposure from these products complicates surgical risk assessment and recovery, particularly in patients with limited access to endocrinology follow-up.
What remains unresolved and what to watch next
Even with this trail of lab tests, recalls, and case reports, major questions remain. None of the cited FDA documents provide data on how many units of Artri King, ADVANCE KING, or related Artri and Ortiga products have been sold, leaving regulators and clinicians without a clear sense of total exposure volume, according to the available notifications on Artri King and on ADVANCE KING. There is also no manufacturer testing data or internal correspondence in the public warning letters, so outside observers cannot see how or when the adulteration began.
The clinical literature is similarly limited. The HPA-axis disruption series tied to Artri King includes three patients, according to the peer-reviewed report on three cases of HPA axis disruption, and the Cushing syndrome case reports describe single individuals. Those papers provide detailed hormone measurements and treatment courses, but they do not yield population-level estimates of how common steroid-induced endocrine disease is among all users of these supplements.
Another gap involves long-term outcomes. The available case reports describe tapering strategies and short-term recovery from adrenal insufficiency after stopping Artri King or Artri Ajo King, according to the articles on iatrogenic Cushing syndrome and on Cushing’s syndrome and Artri King. They do not track patients over years to see whether bone density, cardiovascular risk, or recurrent adrenal crises remain elevated.
For readers, the most immediate consequence is practical. Anyone who has been using an over-the-counter joint-pain supplement under the Artri, Artri King, Artri Ajo King, Ortiga, or ADVANCE KING names faces a documented risk of hidden exposure to prescription-strength dexamethasone and other drugs, according to FDA alerts on Artri and Ortiga products and on ADVANCE KING. Clinicians in emergency rooms and safety-net hospitals are already encountering patients whose unexplained infections, fractures, or blood pressure swings trace back to these hidden steroids.
The latest publicly available regulatory and clinical updates are limited to the documents cited here, so there is no current public tally of how widely these products remain in circulation. The next developments to watch are additional enforcement actions, new recalls, or larger observational studies that could clarify how many patients have experienced hormone disruption from these supplements. Until those data emerge, the record already shows that a popular joint-pain remedy sold over the counter has been tied to hidden hormone-active drugs that can turn chronic pain management into an unrecognized endocrine disease.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
